In a small Tennessee household, the country's deepening political divide has met its match. Amye and Charlie Joseph have been married for 35 years, but they sit on opposite ends of the political spectrum — she is a Republican, he is a Democrat. Yet the Elizabethton couple has found something they can agree on: a shared frustration with pharmacy benefit managers, the controversial middlemen of the prescription drug industry.
Amye Joseph describes the current political climate as an "interesting time," but the tension in her home fades when the conversation turns to the rising cost of their medications. Both she and her husband feel the same way about the companies that sit between patients and their prescriptions, and that mutual annoyance has become a rare source of common ground.
That frustration is directed squarely at CVS Health, a corporate giant that reported $400 billion in revenue last year. The company operates across nearly every corner of the healthcare system: it owns Aetna, a major health insurer; CVS Caremark, one of the nation's dominant pharmacy benefit managers; and CVS Pharmacy, the largest retail pharmacy chain in the United States.
Pharmacy benefit managers, commonly known as PBMs, were originally designed to manage prescription drug plans and negotiate lower prices on behalf of employers and insurers. In theory, they were supposed to act as a check on drug costs, using their size to extract discounts from manufacturers and steer patients toward cheaper options. That is the industry's foundational promise.
In practice, however, these companies have become one of the most criticized players in American healthcare. Critics say PBMs have morphed into profit centers that enrich themselves at the expense of the employers, government programs, and patients they are meant to serve. The result is a rare alignment of Democrats and Republicans, patients and politicians, all pointing at the same target.
Amye Joseph pulls no punches when describing her feelings about CVS. She says the company's drug plan, CVS Caremark, pressures her and her husband to fill prescriptions at CVS stores rather than at their local pharmacy. She also misses the personal connection that once came with visiting a neighborhood pharmacist and resents drug prices that seem to climb without any clear explanation from the companies setting them.
Her conclusion is blunt: the company is not a neutral intermediary at all, but something closer to a machine designed to extract money from consumers. "They're not even a middleman," she said. "They're a money grab for CVS." It is a sentiment that echoes across party lines and state boundaries.
What makes the issue unusual is its political reach. In Washington, D.C., debates over healthcare reform still tend to break along familiar partisan lines, with Democrats and Republicans clashing over the role of government, insurance markets, and regulation. But when it comes to PBMs, lawmakers from both parties have increasingly found themselves on the same side.
That bipartisan disdain is now translating into action at the state level. Tennessee and Arkansas are among the states moving to regulate these pharmacy benefit managers, a sign that the pushback is not merely rhetorical. State legislators appear to be responding to constituent anger that crosses ideological boundaries, driven by stories of patients unable to afford medications or forced away from the pharmacies they trust.
The Josephs' situation illustrates why the issue resonates so broadly. Their household contains both a Republican and a Democrat, yet neither sees the current prescription drug system as fair or transparent. For them, and for many families like theirs, the problem is not abstract policy but an everyday reality: paying more, getting less personal service, and feeling powerless against a conglomerate that controls multiple stages of the drug supply chain.
CVS Health embodies the consolidation that worries critics most. When one company owns the insurer that pays for drugs, the PBM that negotiates drug prices, and the pharmacy that dispenses those drugs, the potential for conflicts of interest is enormous. The company has said its integrated model helps lower costs and improve care, but skeptics argue that such vertical integration gives it too much leverage over where patients go and how much they pay.
The stakes extend far beyond one company. PBMs collectively handle prescriptions for millions of Americans, including those covered by employer plans, Medicare, and Medicaid. Their decisions about which drugs are covered, what patients pay at the counter, and which pharmacies are included in a network can determine whether someone can afford a lifesaving medication or must go without.
As frustration mounts, the political dynamics are shifting. What was once a wonky topic debated among healthcare policy experts has become a kitchen-table issue that voters bring up with their elected representatives. That shift is forcing politicians from both parties to take notice — and to take action, even if they disagree on almost everything else.
The battle over PBMs also highlights a broader dissatisfaction with a healthcare system that many Americans feel no longer works in their favor. Rising premiums, opaque pricing, and corporate consolidation have eroded trust across the political divide. In that environment, PBMs have become a convenient and unifying villain, a rare target that neither party is eager to defend.
For the Josephs, the issue is personal, not partisan. Thirty-five years of marriage have taught them to navigate their political differences, but the couple's shared experience with the pharmacy counter has made the PBM debate feel less like politics and more like common sense. If their small household can find agreement on the issue, it suggests the rest of the country might too.
(0)